Feasibility of Concurrent Chemoradiotherapy with Docetaxel, Cisplatin, and 5-FU for Head and Neck Cancer

DOI DOI Web Site Web Site Web Site 11 References

Bibliographic Information

Other Title
  • 頭頸部癌に対するDocetaxel，Cisplatin，5-FU（TPF）同時併用化学放射線療法の忍容性に関する検討
  • 臨床 頭頸部癌に対するDocetaxel,Cisplatin,5-FU(TPF)同時併用化学放射線療法の忍容性に関する検討
  • リンショウ アタマ ケイブガン ニ タイスル Docetaxel,Cisplatin,5-FU(TPF)ドウジ ヘイヨウ カガク ホウシャセン リョウホウ ノ ニンヨウセイ ニ カンスル ケントウ

Search this article

Description

Background:<br>Concurrent chemoradiotherapy is one of the standard treatment for locally advanced head and neck cancer. Cisplatin is the most feasible regimen of concurrent chemoradiotherapy. However the clinical response has been less satisfactory favorable.<br>The favorable efficacy of chemotherapy with cisplatin and docetaxel, 5-FU (TPF) as induction chemotherapy for head and neck cancer have been reported. However the feasibility of concurrent chemoradiotherapy with TPF has been sparsely reported and has had many limitations. The purpose of this study was to identify the feasibility of TPF concurrent chemoradiotherapy.<br>Materials & Methods:<br>We retrospectively analyzed 60 head and neck cancer patients treated with definitive concurrent TPF chemoradiotherapy. We investigated the treatment completion rate, adverse events, average relative dose intensity, and causes of dose reduction.<br>Results:<br>The treatment completion rate was 98.3% and ARDI was 70%. Hematological adverse events over Grade 3 were observed as leukopenia 60.9%, neutropenia 60%, anemia 11.8%, and thrombocytopenia 6.4%. Febrile neutropenia was observed as 16.4% patients however no treatment related death was observed.<br>Conclusion:<br>Concurrent chemoradiotherapy with TPF was a feasible treatment for head neck cancer. We should continuously investigate the efficacy of this treatment.

Journal

References(11)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top